B

BiohacksAI

Evidence-Based Biohacking

Patent Pending

PRKACG

MOLECULAR TARGET

protein kinase cAMP-activated catalytic subunit gamma

UniProt: P22612NCBI Gene: 55686 compounds

PRKACG (protein kinase cAMP-activated catalytic subunit gamma) is targeted by 6 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).

Compounds Targeting PRKACG

Ranked by bioassay confidence score (PubChem active assay count × evidence quality).

#CompoundConfidenceActive Assays
1at 92833.0921
2pf 037583093.0019
3amg 2082.087
4losmapimod1.795
5hydroxyfasudil [Supplementary Concept]1.102
6alpelisib0.691

About PRKACG as a Drug Target

PRKACG (protein kinase cAMP-activated catalytic subunit gamma) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 6 compounds with documented PRKACG interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.

PRKACG inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.